GB Sciences Statistics
Total Valuation
GB Sciences has a market cap or net worth of $2.03 million. The enterprise value is $3.53 million.
| Market Cap | 2.03M |
| Enterprise Value | 3.53M |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
GB Sciences has 406.07 million shares outstanding. The number of shares has increased by 6.40% in one year.
| Shares Outstanding | 406.07M |
| Shares Change (YoY) | +6.40% |
| Shares Change (QoQ) | +1.88% |
| Owned by Insiders (%) | 12.22% |
| Owned by Institutions (%) | n/a |
| Float | 375.46M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.03
| Current Ratio | 0.03 |
| Quick Ratio | n/a |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -336,753.04 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -4,101.69% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.01M |
| Employee Count | 3 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, GB Sciences has paid $2.70 million in taxes.
| Income Tax | 2.70M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -58.17% in the last 52 weeks. The beta is 0.35, so GB Sciences's price volatility has been lower than the market average.
| Beta (1Y) | 0.35 |
| 52-Week Price Change | -58.17% |
| 50-Day Moving Average | 0.01 |
| 200-Day Moving Average | 0.01 |
| Relative Strength Index (RSI) | 46.72 |
| Average Volume (30 Days) | 127,835 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | -624 |
| Operating Income | -1.58M |
| Pretax Income | -3.76M |
| Net Income | -6.03M |
| EBITDA | -1.16M |
| EBIT | -61.66B |
| Earnings Per Share (EPS) | -$0.02 |
Balance Sheet
The company has $17,459 in cash and $1.51 million in debt, giving a net cash position of -$1.49 million or -$0.00 per share.
| Cash & Cash Equivalents | 17,459 |
| Total Debt | 1.51M |
| Net Cash | -1.49M |
| Net Cash Per Share | -$0.00 |
| Equity / Book Value | -4.85M |
| Book Value Per Share | -0.01 |
| Working Capital | -4.77M |
Cash Flow
In the last 12 months, operating cash flow was -$943,120 and capital expenditures $1,330, giving a free cash flow of -$941,790.
| Operating Cash Flow | -943,120 |
| Capital Expenditures | 1,330 |
| Free Cash Flow | -941,790 |
| FCF Per Share | -$0.00 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
GB Sciences does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.40% |
| Shareholder Yield | -6.40% |
| Earnings Yield | -297.20% |
| FCF Yield | -46.39% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on October 31, 2013. It was a reverse split with a ratio of 1:10.
| Last Split Date | Oct 31, 2013 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |